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ABSTRACT 
 
Title:  Autonomic dysfunction in chronic inflammatory demyelinating polyneuropathy 
 
Name of Candidate: Suresh Babu  
 
Course:  D.M. branch I, Neurology August 2014  
 
Objective:  To assess the frequency, severity and spectrum of autonomic dysfunction in patients 
with chronic inflammatory demyelinating polyneuropathy and to correlate autonomic 
dysfunction with the associated sensory motor deficits. 
 
Methods: Autonomic function was prospectively analyzed in 23 patients meeting CIDP criteria 
.Autonomic dysfunction was quantified by quantitative autonomic function tests (AFTs) using 
Finopres. The degree of autonomic dysfunction quantified by using modified CASS. Heart rate 
variability was assessed using power spectrum analysis. Autonomic symptoms quantified by 
using COMPASS 31. Severity of neurologic deficits was measured with total neuropathy score 
(TNS).  
 
Results: Patients mean age was 47.14±13.46 years with duration of illness 4.48±4.30 years. 
15 of 23(65%) patients having autonomic symptoms, common symptoms were bowel and sicca 
symptoms. Autonomic deficits were common (Modified CASS = 3.26 ± 1.91) (19/23; 82%) with 
moderate severity 11/23(47.8%).Autonomic dysfunction involving both parasympathetic (70%) 
and sympathetic arms (60%).Spectral analysis of HRV showing abnormality in sympathetic arm.   
Autonomic deficits did not relate to autonomic symptoms severity, somatic deficits, duration of 
disease, severity of disease and temporal profile of disease 
 
Conclusion: .There is a high Prevalence of autonomic dysfunction in patients with CIDP(80%).  
The parasympathetic arm (70%)was more involved than sympathetic(60%). 
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INTRODUCTION 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a common cause of autoimmune 
neuropathy, described first in 1958 by James Austin as steroid-responsive relapsing 
polyneuropathy.(1) In 1975 the disease was characterized at the Mayo Clinic by Prof Peter Dyck 
and the term CIDP was  coined . (2) The prevalence of CIDP from current published data ranges 
from 1 to 7.7 per 100,000, and increases with advancing age with a peak incidence at 40–60 
years of age.(3) CIDP is considered to be a disease with predilection for large myelinated fibers 
over small myelinated and unmyelinated fibers.(4) In view of the profound motor weakness, 
emphasis has always been on the motor disabilities and the autonomic dysfunction in these 
patients’ has not been addressed in the Neurology Clinic setting. Both myelinated and 
unmyeminated fibers are affected in patients with CIDP leading to autonomic dysfunction (5) 
Based on previous studies, the   prevalence of autonomic deficits in CIDP has been found to be 
21% to 76%. (5)(6)(7)  
However, most of the studies were retrospective and factors like selection and recall bias could account 
for the high variability in prevalence of autonomic dysfunction. There is a paucity of Quantitative studies 
assessing autonomic dysfunction are lacking in both Western and Indian setting. Hence, there is a need 
for a prospective study to accurately ascertain the actual prevalence of autonomic dysfunction, both 
clinical and subclinical in a   cohort of patients’ with CIDP and to quantify the degree of dysfunction.  
Identifying the domains’ of involvement will also help in addressing appropriate treatment strategies.  
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AIMS AND OBJECTIVES 
 
1. To assess the frequency of occurrence, severity and spectrum of autonomic dysfunction in 
patients with CIDP 
 
2. To correlate autonomic dysfunction with the associated sensori- motor deficits 
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REVIEW OF LITERATURE 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common cause of a 
Chronic Autoimmune neuropathy. Various criteria have been developed to define the disease.  
Some are stringent criteria and some are based on clinical response, that ensure early recognition 
and early treatment with immunomodulation/ immunosuppressant drugs.  
Despite ongoing clinical challenges with the diagnosis and definition, CIDP can be practically 
viewed as the chronic spectrum of Guillain–Barré syndrome, owing to similarities in 
electrophysiological, histolopathological and immunopathogenesis. (8).  
 CIDP differs from AIDP, by its temporal profile, course of disease and responsiveness to 
immunosuppressive agents like steroids. (8)  Chronic inflammatory demyelinating poly 
radiculoneuropathy (CIDP) is a heterogeneous disorder. CIDP differs from AIDP as former 
develops over  more than 2 months, where AIDP has an acute onset.(8) 
CIDP although is being increasingly recognized and diagnosed clinically, the lack of definitive 
diagnostic test makes the diagnosis occasionally challenging. 
 
Epidemiology: 
 Available previous literature showing varied prevalence ranging from 1 to 7.7 per 100,000 and it 
has high incidence at 4- 6 decade.(3) 
The discrepancies in prevalence is linked to several factors, like differences in clinical,  
electrophysiological criteria and genetic factors .(9)(10)  The disease can occur at any age with a 
mean age of onset being 47.6 years and has a higher prevalence in males than in females.(11)  
Although a relapsing course seems more common between the second and fourth decade, a 
chronic non relapsing course is more common between the fifth and the seventh decade.(3) 
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Pathogenesis: 
In CIDP, organ specific damage to peripheral nerves due to auto activation of cellular and 
humoral immunity due to loss of self tolerance(12) 
In some individuals immune response to various pathogenic factors leads to break down in self 
tolerance and results in autoimmune disorders. The inciting factors known to share epitopes with 
the host’s affected tissue.(13)Most commonly various infections were implicated in breakdown 
of self tolerance. 
A high incidence of CIDP in melanoma or patients receiving vaccinations with melanoma lysates 
due to breakdown in self tolerance.(13) 
 
FIGURE 1: Pathogenesis of CIDP 
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Cellular immune response 
Due to unknown antigens systemic T cells are activated which generate inflammatory lesions in 
the nerves through blood nerve barrier breakdown by a process which includes homing, adhesion 
and transmigration. (14) 
Levels of soluble adhesion molecules, chemokines, cytokines and matrix metallo-proteinases are 
increased in the serum, endothelial cells and CSF of patients with CIDP, all of which facilitates 
lymphoid cell transmigration across the blood–nerve barrier. Derangement of the blood nerve 
barrier is known to happen due to down regulation of tight junction proteins.(15) Macrophages 
and Schwann cells present antigen to the CD4+ T cells, through expression of the co-stimulatory 
molecules CD80 and CD86, which bind to the counter-receptors on the CD4+ T cells i.e., 
CTLA-4 and CD28.(16)(17) Then T cells undergo clonal expansion thereby activating resident 
endoneurial or passenger macrophages. Macrophages are the final effector cells that are 
associated with the demyelinating process. Macrophages release an variety of potentially toxic 
substances which cause cytotoxic activity against Schwann cells..(18) 
 
Humoral immune response: 
Autoantibodies have been implicated in the pathogenesis of chronic inflammatory demyelinating 
polyneuropathy since more than two decades. This observation was based on c.s.f oligoclonal 
IgG bands and presence of immunoglobulins and complements on myelinated nerve fibers. .(19) 
These autoantibodies were implicated in the conduction block and demyelination in experimental 
models.(20). Recent studies indicate that antibodies to various glycolipids or myelin proteins 
P0were frequently detected than controls.  (20)(21)(22)(23)  
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Passive transfer of GM1 antibodies from CIDP patients to experimental animals was found to 
suppress sodium currents in myelinated nerve fibres in experimental animals.(24) Other than 
myelin- directed antibodies, cytokines, nitric oxide and complements may be involved in the 
pathogenesis of demyelination and conduction block. Removal of auto antibodies along with 
toxic substances like cytokines, nitric oxide by plasma exchange has shown to improve prognosis 
in CIDP. It probably indicates that activated B cells play a role in CIDP.    
 
Target antigens: 
Despite detailed investigations the target antigens involved in the pathogenesis of CIDP is yet to 
be determined.  It is postulated that the antigeninc targets may be located within the non-compact 
myelin and in the points of Schwann cell–axon interaction. Molecules  such as neurofascins 
gliomedin and contactin (contactins-2, CASPR1, connexin, neural cell adhesion molecule, 
cadherin, ankyrin and others), are the postulated  target antigens in human autoimmune 
neuropathies.(25)(26) 
 
Clinical features: 
Acute inflammatory demyelinating neuropathy (AIDP) and CIDP have similar clinical findings, 
but as the terms imply, the time course is defined by a peak deficit within 4 weeks in AIDP, and 
after at least 8 weeks in CIDP. Typical cases of CIDP are fairly symmetric, and motor 
involvement is greater than sensory. Typical CIDP is characterized by a progressive, symmetric, 
proximal and distal muscle weakness, paresthesias and impaired balance, which evolve slowly 
over at least 2 months. The course may be slowly progressive or relapsing/remitting.(27) A 
classic clinical feature is proximal limb weakness, which distinguishes CIDP from the large 
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group of far more commonly encountered distal polyneuropathies. An important differentiating 
clinical finding is the discrepancy between the degree of weakness and the absence of atrophy in 
affected muscles. This finding strongly suggests nerve demyelination, as opposed to axonal loss 
in which atrophy may be prominent. Tendon reflexes are reduced or absent in all extremities.  
 
Sensory involvement is characterized by numbness, distal paresthesias, poor balance, and 
impaired proprioception. (28)Sensory involvement is usually greater for vibration and position 
sense than for pain and temperature, reflecting the involvement of large myelinated fibers. As 
opposed to the motor involvement, sensory involvement tends to follow a distal to proximal 
gradient, although finger involvement frequently occurs as early as toe/foot involvement. Cranial 
nerve involvement is noted in less than 15% of patients. The common nerves involved are facial, 
bulbar and extra ocular nerves. Vision loss may be present rarely and is because of pseudo-
tumour cerebri, which occurs as a result of high protein content in cerebro-spinal fluid. 
Autonomic dysfunction and ventilatory failure has been reported in less than 10% of cases, much 
in contrast to GBS. Constipation and urinary retention  are seen occasionally  but not early into 
the disease.(29) 
Occasionally,  patients may present with back pain, lumbar canal stenosis and cauda equina 
syndrome  due to marked nerve root hypertrophy.  
 
Atypical CIDP: 
CIDP is a multifocal disease with demyelination affecting spinal roots, plexuses and proximal 
nerve trunks. (8)(30)The clinical manifestations may hence differ between patients resulting in   
myriad variation in presentation. Patients with atypical clinical features are grouped within the 
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broader category of chronic acquired demyelinating polyneuropathy along with CIDP. This 
group shares similar electrophysiological features, csf findings and response to 
immmunotherapies.(28)(31) 
 
Atypical CIDP includes pure motor, pure sensory and ataxic patterns, as well as a multifocal 
pattern in which weakness and sensory loss develop in the distribution of multiple nerves. 
 
The motor variant:  
It is a generalized, pure motor demyelinating neuropathy.  widespread proximal and distal limb 
weakness, relative symmetry, no sensory involvement, and response to corticosteroids 
distinguish it from multifocal motor neuropathy.(32)(33) 
The pure sensory syndrome:  
It presents with distal sensory loss, but prominent demyelinating motor abnormalities on EMG 
studies.(34)(35) 
Ataxic CIDP variants:  
It consists of 2 variants 
1) Patients present with sensory ataxia which simulate a sensory ganglionopathy, with absent 
sensory potentials and normal motor studies. Nerve biopsy may be required to establish the 
diagnosis.(36) 
2) Clinical presentation is similar with sensory ataxia and large fiber sensory loss. However  
nerve conduction studies are normal. Abnormal somatosensory evoked potentials suggest 
sensory root involvement. Biopsy of the nerve rootlet similar to that of CIDP and this condition 
termed as chronic immune sensory polyradiculopathy.(37)  
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Multifocal Acquired Demyelinating Sensory and Motor Neuropathy (MADSAM or “Lewis-
Sumner Syndrome”): 
Clinical presentation is that of a multifocal neuropathy since conduction block is found in 
affected nerves.  However in contrast to multifocal motor neuropathy they also have involvement 
of sensory nerves and good response to steroids.(38) 
A paraparetic form of CIDP: 
It is associated with regional leg weakness, sensory loss, striking nerve root hypertrophy, and 
gadolinium enhancement of the lumbosacral nerve roots on magnetic resonance imaging (MRI) 
studies.(39) 
Distal Acquired Demyelinating Symmetric Neuropathy (DADS): 
It simulates a distal sensorimotor neuropathy with demyelinating electrophysiology suggestive of 
CIDP. DADS may or may not be associated with paraproteinemia.  DADS without 
paraproteinemia predicts good response to therapy similar to typical CIDP, unlike DADS with 
paraproteinemia. (40) 
 
Laboratory features: 
CSF examination, NCS, and nerve biopsy are the key laboratory studies that support a diagnosis 
of CIDP. Magnetic resonance imaging (MRI) may reveal spinal nerve root enlargement. Serum 
electrophoresis to detect paraproteinemia is done to exclude a plasma cell dyscrasia. 
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Nerve conduction studies: 
Electrophysiology is a key part of  the diagnostic investigation in CIDP. There are currently 17 
published sets of electro-diagnostic criteria for acquired demyelinating neuropathies, all 
requiring some combination of (41) 
(1)Reduced conduction velocities,  
(2) Prolonged distal motor latencies,  
(3) Prolonged F-wave latencies  
(4) Conduction block / temporal dispersion 
 
Kelly in 1983  put  forth the first criteria to distinguish neuropathies associated with monoclonal 
proteins as axonal or demyelinating. Albers and Kelly in 1989 revised the initial criteria and 
specified prolonged distal latency, conduction velocity slowing, prolonged F wave latency, or a 
temporal dispersion in two or more nerves.  A third criteria by AAN was proposed but was found 
to have a low sensitivity. Thaisetthawatkul and colleagues showed the usefulness of adding  
dispersion of distal motor action potentials win diagnostic criterion.(42) Currently the 
EFNS/PNS 2010 criteria seems to be  best  in identification of patients with CIDP. This criteria 
includes prolonged distal CMAP duration in one nerve with one or more other demyelinating 
parameter in another nerve as supportive of definite CIDP, a normal sural with abnormal median 
or radial SNAP pattern and sensory conduction velocity < 80 % of lower limit of normal (<70 % 
if SNAP amplitude < 80 % of lower limit of normal) as supportive criteria.(43) 
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Cerebrospinal fluid analysis: 
A lumbar puncture is indicated in most patients suspected of having CIDP. Approximately 90% 
of patients with CIDP have elevated CSF protein concentrations (> 45 mg /dL). The diagnosis of 
CIDP cannot be excluded based on a normal CSF protein concentration. In the past elevated 
protein considered as mandatory. However, protein content can be normal in at least 10% of 
patients, and the criterion is now considered supportive. The cell count is usually normal, 
although as many 10% of patients have greater than 5 lymphocytes/mm
3
. AAN criteria has 
suggested that there should be fewer than 10 white blood cells in the spinal fluid, and fewer than 
50 cells in patients with HIV infection. Accordingly, the presence of a CSF pleocytosis suggests 
evaluation for co-infection/ non-infectious granulomatous diseases. 
 
Other laboratory investigations: 
Somatosensory evoked potentials are useful in patients with chronic demyelinating neuropathies 
as root involvement is not accessible to conventional nerve conduction studies.(44) 
This technique might be especially useful when assessing for proximal involvement of sensory 
nerves in patients with normal sural sensory potentials. 
 
MRI of spine with gadolinium sometimes demonstrate nerve root enhancement in some  
suspected CIDP patients due to breakdown of the blood–nerve barrier at the root level and root 
hypertrophy at the lumbar or cervical level in patients with CIDP and can rarely cause clinical 
findings attributable to lumbar or cervical canal stenosis. (45)As inflammation can be 
widespread along nerves in CIDP, contrast enhancement and hypertrophy are sometimes shown 
by conventional MRI at the plexus level. 
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Nerve biopsy: 
CIDP is demyelinating disorder involving the spinal roots, plexuses, and nerve trunks in a diffuse 
manner.  
The yield of biopsy in the confirmation in the diagnosis of CIDP was low, due to multifocal 
nature of disease. Only in 10-15% of biopsy specimens showing inflammatory changes, it was 
demonstrated in large series of patients in previous studies. Nerve biopsy  features were varied 
from abnormal about 60%(axonal, demyelinating, inflammatory).to normal about 40%(27) 
The demyelinating lesions involving proximal nerve leads to distal axonal degeneration resulting 
in loss of large myelinated fibers. In such cases an axonal type of nerve conduction abnormalities 
resulting in misdiagnosis as chronic idiopathic axonal polyneuropathy rather than CIDP. In these 
cases, nerve biopsy might be of value for diagnosis of CIDP.(46) 
According to the EFNS/PNS CIDP guidelines, biopsy chosen  from the nerve which was affected 
clinically and electro-physiologically.  
The classic pathologic features of CIDP include demyelination, remyelination (onion 
Bulbs), endoneurial edema, and inflammatory cell infiltrates in the epineurium and endoneurium 
usually with preferential involvement of the nerve roots. These infiltrates consists of  CD81 and 
CD41 lymphocytes and macrophages within the endoneurium. The perivascular macrophages  in 
clusters in endoneurium suggest the diagnosis of CIDP on nerve biopsy. Analysis of teased fibers 
is probably the most sensitive method of demonstrating demyelinating changes, which are found 
in 50% to 80% of nerve biopsy specimens. Nerve biopsy considered in patients having  atypical 
features or poor response to treatment or high suspicion of alternative diagnosis. 
 
 
19 
 
Diagnostic criteria of CIDP: 
During last 2 decades, there are different published criteria for diagnosis of CIDP and there still 
is no consensus optimal approach to the diagnosis.  
They published criteria includes clinical, laboratory, and electro-diagnostic criteria with definite, 
probable, and possible categories. The differences between the different criteria related to 
definition of the clinical profile, electrophysiological criteria for demyelination and requirement 
for nerve biopsy. The most recent EFNS/PNS 2010 guideline attempts to provide diagnostic 
criteria for CIDP based on currently available literature plus expert opinion. It contains clinical, 
electro diagnostic and supportive criteria. The diagnostic criteria are mentioned in the appendix.  
 
CIDP and Autonomic dysfunction 
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated 
disorder affecting large myelinated fibers more than small myelinated and unmyelinated fibers. 
CIDP is characterized predominantly by motor deficits and mild sensory deficits with autonomic 
nervous system involvement being not well characterized in previous reports. The prevalence of 
autonomic dysfunction in patients with CIDP varies from 21%-76%. Studies assessing 
autonomic dysfunction in CIDP patients by quantitative methods are lacking in both western and 
Indian literature. It is postulated that autonomic dysfunction in CIDP is probably due to 
demyelination with conduction blocks affecting the vagus nerve and preganglionic sympathetic 
efferent fibers or small myelinated and unmyelinated afferent fibers. Lyu et al studied 
cardiovascular autonomic dysfunction and sympathetic skin response in 12 CIDP patients and 
reported subclinical abnormalities involving both a parasympathetic and sympathetic arms in 
25% of patients. SSR abnormality was found in 50% of patients examined.(6) 
20 
 
Yamamoto et al case reports showed dominant autonomic nervous involvement does not exclude 
a diagnosis of CIDP.(47) Stambolis et al studied autonomic dysfunction in 17 CIDP patients 
showing a higher frequency autonomic nervous system involvement in CIDP when compared to 
previous studies. Quantitative autonomic function tests revealed a dysfunction in 76% of 
patients, involving both parasympathetic and sympathetic arms.(48) 
Figueroa et al studied autonomic dysfunction in 47 CIDP patients retrospectively using the 
CASS, a validated instrument for quantitative autonomic functions. Autonomic symptoms were 
relatively rare and if present manifest as gastrointestinal and genitourinary complaints. 
Autonomic deficits were frequent (47%) but very mild and limited to cholinergic arm with 
sparing of adrenergic arm. There was no correlation of autonomic dysfunction with the duration 
or severity of the somatic symptoms.(4)(47)Sakakibara et al. studied the micturition disturbances 
in CIDP patients and found symptoms suggestive of bladder dysfuction in 8 of 32 patients. 
Urodynamic studies on four symptomatic patients showed disturbed bladder sensation in two, 
bladder areflexia in one, and neurogenic changes of the external sphincter in one, indicative of 
peripheral parasympathetic and somatic nerve dysfunctions. Cystometry had shown detrusor 
overactivity in two patients without any evidence of CNS involvement. (49) Chiang et al. studied 
epidermal nerve density (END) and thermal thresholds in 18 chronic inflammatory 
demyelinating polyneuropathy (CIDP) patients. This study showed significantly lower END in 
patients with autonomic symptoms (4 in 18) than did those without, indicating that epidermal 
nerve fibers were more depleted in the presence of autonomic impairment.(50) 
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MATERIALS AND METHODS 
Study setting- 
 The study was conducted in Christian Medical College and Hospital, a 2500 bedded tertiary 
hospital in South India. It was conducted in the Department of Neurology. Eligible subjects were 
recruited from the Neurology outpatient clinics or wards.  
 
Study design-  
The study design was prospective cross-sectional study.  
The study design and methods were approved by the Institutional review board of Christian 
Medical College, Vellore.  
 
Participants- Inclusion criteria 
Patients diagnosed to have CIDP by EFNS/PNS 2010 criteria were included in the study. The 
criteria are mentioned in appendix. 
 
 
Patients with peripheral neuropathy seen in the department of Neurology, Christian medical 
college, Vellore were screened for inclusion in the study with age greater than 18 years fulfilling  
European Federation of Neurological Societies/Peripheral Nerve Society criteria 
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Subject enrollment:  
If a patient fulfilled criteria for inclusion then they were approached for informed consent. If the 
patient consented clinical and demographic data was collected the patient underwent a 
standardized neurological examination.  
 
Total Neuropathy Score was used as a standardized measurement of severity of somatic 
neuropathic deficits, motor, sensory and autonomic. (65) 
The total score is expressed as a composite score ranging from 0 (no impairment) to 40 (maximal 
impairment). The scoring system is shown in appendix. 
COMPASS 31 scoring system was used to score severity of autonomic symptoms. The minimum 
raw score is zero and Maximum is 75.(66)The scoring system is shown in appendix. 
 
Seven quantitative autonomic function tests (AFTs) were used for assessment: Valsalva ratio, 
30/15 ratio, and inspiration– expiration difference for parasympathetic function; and tilt test, 
handgrip test, beat to beat BP response to Valsalva maneuver and sympathetic skin response for 
sympathetic function.  
 
Cardiovagal functions tests 
i. RR interval variability following deep breathing- the patient sits quietly 
and then breathes deeply at a rate of 6 breaths per minute. The ratio of the 
maximum – minimum heart rates to deep breathing is measured.   
Figure 3 showing heart rate variation with deep breathing 
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ii. RR interval variability on standing (30:15 ratio – the ratio of RR intervals 
of 30
th
 and 15
th
 beat after standing). 
iii. Valsalva ratio (longest phase 4 bradycardia RR interval divided by 
shortest phase 3 tachycardia RR interval, recorded when performing the 
Valsalva manoeuvre). 
 
Valsalva maneuver will be performed in supine position; the test will be started after patient is 
comfortable and relaxed.After 2-3 practice scissions once patient become comfortable with 
procedure,he is instructed to take a deep breath and blow into the syringe which is connected to a 
manometer. Patient is asked to maintain a pressure of 40 mm Hg for 15 seconds. Same procedure 
repeated after 3 minutes, total 3 times and most appropriate maneuver will be selected for 
evaluation. The following parameters will be measured from maneuver  – Figure 4 showing 
difference stages of Valsalva maneuver 
 
1. Valsalva ratio. 
2. Maximum early phase 2 drop in the mean blood pressure  
3. Late phase 2 peak mean blood pressure (recovery). 
4. Phase 4 mean blood pressure overshoot. 
 
2. Adrenergic functions 
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i. BP response to tilt/ standing for three minutes (measured at one minute 
and three minutes- a drop of more than n 20 mm Systolic or 10 mm 
diastolic is considered abnormal)(2) 
 
After connecting and ensuring proper placement of blood pressure sensor, 
baseline blood pressure will be measured for 5-10 minutes. Then patient 
will be tilted up to 70 degree smoothly within 5-10 seconds (ensuring 
patient safety) .Then blood pressure will be measured every minute. 
During this period patient will be observed for the presence of any 
discomfort, chest pain, shortness of breath, dizziness, lightheadedness, and 
syncope. In case of any sign of an emerging adverse event test will be 
terminated based on clinical judgment. Duration of the tilt will be at least 
10 minutes and continued for 30 minutes if no obvious abnormalities are 
detected .On completion of test patient will be tilted back to baseline 
position.  
 
ii. Beat to beat BP response to Valsalva maneuver. (1) BP response to 
immersion in cold  water (a diastolic rise of < 15 mmHg is considered 
abnormal) 
 
3. SSR (sympathetic skin response)  
Standard silver surface electrodes will be used for the recording. They will be placed on 
sites with maximum eccrine sweat gland density –active electrode on palms and soles, 
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respectively, reference electrodes on the dorsum of hand and foot, respectively. The 
response is processed by standard electromyography. Deep inspiration will be used as 
stimulus to evoke SSR. Presence or absence of wave forms is noted. 
Composite score of autonomic dysfunction - CASS will be calculated based on the above data. 
These tests will help in identifying the domain of autonomic nervous system affected and the site 
of involvement. ). (67). In view of lack of facilities for QSART, SSR was used to assess 
sudomotor functions. It was incorporated in to CAS scoring and a modified CAS score was used 
for analysis and it has not been validated yet. 
 
Equipment and data acquisition 
The Finometer  PRO™ is a noninvasive beat to beat blood pressure measurement and 
haemodynamic monitoring system that incorporates proprietary Modelflow methodology for 
cardiac output measurement and other hemodynamic parameters. 
The finometer advantage is its accurate and robust continuous measurement in an all-in-one 
concept. The finometer not only captures the continuous blood pressure waveform, but also 
automatically computes up to 15 important beat to beat hemodynamic parameters including: 
1. Systolic, diastolic and mean arterial pressures 
2. Cardiac output. 
3. Stroke volume  
4. Total peripheral resistance 
5. Pulse rate variability 
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6.  Inter-beat interval 
7. Baro-reflex sensitivity 
The finometer PRO provides accuracy through return to flow calibration using an inflatable arm 
cuff and direct graphic parameter visualization on a built-in flat screen 
Measurement  
All AFTs were performed in the laboratory under standardized conditions. All measurements 
were performed in a silent room with a temperature of 22°–25°C. 
Power Spectrum Analysis 
PSA was obtained after 15-min rest in a lying position for 5 minutes s and after  a 30° head-up 
tilt for 5 minutes.  Data was exported from Finopres machine. CMCdaq version 1.3, a data 
acquisition, review and analysis soft ware was used to study heart rate variability and to calculate 
the power spectrum using Fast Fourier Transformation. The spectral components were obtained 
by harmonic Fourier analysis in the 0.0033–0.5 Hz frequency range, with the power reflecting 
the square of the amplitudes. LF and HF power were calculated by integrating the spectra over 
the 0.04–0.15 Hz and 0.15–0.40 Hz ranges. The resulting power was unit less.  
Variables 
1. Demographic data 
2. Total neuropathy score 
3. Neurological examination 
4. Nerve conduction studies 
5. Sympathetic skin response 
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Study outcome: 
Primary outcome was autonomic dysfunction as detected by COMPASS 31 score or autonomic 
function testing detected by modified CASS score.  
 
Statistical Analysis: 
Data entry was done using SPSS software (version 16). Statistical calculations were done using 
SPSS software. Chi-square test was used to compare categorical variables, and student t test was 
used for comparison of continuous variables. Odds ratio (OR) and confidence intervals (CI) were 
calculated. P value of less than 0.05 was considered statistically significant. The Spearman rho 
tested correlations among continuous variables. 
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RESULTS  
 
Among the patients attending with peripheral neuropathy to CMC, Vellore, neurology 
department in last 6 months, 23 patients met clinical and electrophysiological criteria for CIDP. 
 
All patients had negative hematologic, infectious, endocrine, metabolic, rheumatologic, and 
myeloma screening. 
 
The study population comprised of 87% males and 13% of females. 
The mean age at onset of symptoms was 43.04±11.86 years. 
The mean age at the time of autonomic testing was 47.14±13.46 years and duration of illness was 
4.48±4.30 years. 
 
Among 23 patients temporal profile shows insidious onset and progressive course in 12/23(52%) 
of patients, 9/23(39%) had remitting and relapsing course and 2/23(9%) had acute onset of 
CIDP. 
 
At the time of autonomic testing average total neuropathy score was 20.26 ± 4.88 and average 
COMPASS 31 score was 7.00 ± 4.19. 
 
Among 23 patients, 7 patients were associated with MGUS. In our study 17/18 patients were 
immunotherapy responsive. Table 1 showing Demographic and disease characteristics of patients 
with CIDP 
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Table1: Demographic and disease characteristics of patients with CIDP: 
 
                                                                 
Characteristics 
 
Values 
 
Age at onset, years, mean ± SD  
 
43.04±11.86 
 
Male, n/t (%)  
 
20/23(87) 
 
At autonomic testing 
 
 
      Age, years, mean ± SD 
 
47.14±13.46 
  
      Disease duration, years, mean ± SD 
 
4.48±4.30 
 
Acute onset CIDP, n/t (%) 
 
2/23(9) 
 
Progressive course, n/t (%) 
 
12/23(52) 
 
Relapsing and remitting, n/t (%) 
 
9/23(39) 
 
Motor > sensory, n/t (%) 
 
18/23(78) 
 
Immunotherapy responsive, n/t (%) 
 
17/18(94) 
 
CSF 
 
 
          Nucleated cells (cells/dL), mean ± SD 
 
4.96 ± 5.07 
 
           Protein (mg/dL), mean ± SD 
 
117.13 ± 100.97 
 
COMPASS 31 score 
 
7.00 ± 4.19 
 
Total neuropathy score(TNS) 
 
20.26 ± 4.88 
 
CIDP associated with MGUS, n/t (%) 
 
7/23(30) 
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In our study 18 of 23 had autonomic symptoms, most common symptoms were bowel 
complaints and sicca symptoms as shown in table to 2. 
 
 
Table 2: Summary of autonomic symptoms in patients with CIDP: 
 
 
Symptoms 
 
No. of patients  
No. of patients with 
additional 
symptoms 
Most common 
additional symptom 
 
Gastrointestinal 
 
12/23 
 
12/12 
 
Sicca symptoms 
 
Genitourinary 
 
5/23 
 
5/5 
 
Sexual dysfunction 
 
Secretomotor (sicca) 
 
15/23 
 
14/15 
 
Gastrointestinal  
 
Orthostatic intolerance 
 
6/23 
 
6/6 
 
Sicca symptoms 
 
Sexual dysfunction 
 
7/23 
 
7/7 
 
Gastrointestinal 
 
Vasomotor (Flushing) 
 
4/23 
 
4/4 
Gastrointestinal and 
sicca symptoms 
 
Sudomotor 
 
11/23 
 
11/11 
 
Sicca symptoms 
 
 
In our study 19 of 23(82.6%) patients had quantitative autonomic dysfunction.14 of 23(60.9%) 
patients had sudomotor dysfunction, 18 of 23(78.3%) patients had cardiovagal dysfunction and 
18 of 23(68.2%) had adrenergic dysfunction. In our study 8 of 23(34.7%) had mild autonomic 
dysfunction, 11 of 23(47.8%) had moderate autonomic dysfunction assessed by modified CASS. 
As shown in tables 3 – 6. 
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Table 3: Severity of adrenergic score in patients with CIDP: 
 
 
Adrenergic score 
 
              n/t (%) 
 
                       0 
 
             8/23(34.7) 
 
                       1 
 
             4/23(17.3) 
 
                       2 
 
             5/23(17.4) 
 
                       3 
 
             4/23(17.4) 
 
                       4 
 
             2/23(8.7) 
 
 
 
 
Table 4: Severity of cardiovagal dysfunction in patients with CIDP 
 
 
Cardiovagal score 
 
      n/t (%) 
 
                           0 
 
      5/23(21.7) 
 
                           1 
 
     12/23(52.2) 
 
                           2 
 
     6/23(26) 
 
                          3 
 
       0(00 
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Table 5: Severity of sudomotor dysfunction: 
 
 
Sudomotor score 
 
      n/t (%) 
 
                             0 
 
    9/23(39.2) 
 
                             1 
 
    12/23(52.2) 
 
                            3 
 
    2/23(8.70) 
 
 
 
Table 6: Prevalence and Severity of autonomic deficits in patients with CIDP 
 
 
Autonomic function tests abnormalities 
 
         n (%) 
 
Total   
 
        19/23 (82.6) 
 
Sudomotor  
 
       14/23(60.9) 
 
Cardiovagal  
 
       18/23(78.3) 
 
Adrenergic  
 
       15/23(65.2) 
 
Modified CASS score, a mean ± SD 
 
 
Sudomotor (0–3) 
 
       0.61±0.722 
 
Cardiovagal (0–3) 
 
        1.09±0.733 
 
Adrenergic (0–4) 
 
        1.48±1.47 
 
Total (0–10) 
 
      3.26 ± 1.91 
 
Total Modified CASS (1- 3), n (%) 
 
     8/23(34.7) 
 
Total Modified CASS (4-6), n (%) 
 
      11/23(47.8) 
 
Total Modified CASS (6-10), n (%) 
 
       0(0) 
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Blood pressure changes in Valsalva maneuver showed 4 of 23(17.4%) had 20-40 mmHg fall in 
blood pressure during early phase 2 and 2 of 23(8.7%) had more than 40 mmHg fall in blood 
pressure. Blunted late phase 2 response was seen in 13 of 23(56.5%) patients and 7 of 23(30.4%) 
had absent phase 4 blood pressures over shoot as shown in table 7. 
 
 
Table 7: Blood pressure changes in Valsalva maneuver in patients with CIDP: 
 
 
Exaggerated early blood pressure phase 2 fall,  
 
n(%) 
 
                                    ≤ 20% 
mmHg(normal) 
 
19/23(74) 
 
                                    20-40 mm Hg 
  
4/23 (17.40) 
 
                                          ≥ 40 mm Hg 
 
2/23(8.70) 
 
Normal late phase 2 response, n/t (%) 
 
10/23(43.50) 
 
Blunted late phase 2 response, n/t (%) 
 
13/23(56.50) 
 
Normal phase 4 blood pressure over shoot, n/t 
(%) 
 
16/23(69.60) 
 
Absent phase 4 blood pressures over shoot, n/t 
(%) 
 
7/23(30.4) 
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Figure 2:  Stages of Valsalva maneuver Red colour indicate blood pressure  and blue colour 
indicate pulse rate. X-axis indicate time and Y- axis indicate pulse rate and blood pressure  
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5 of 23(21.7%) patients had orthostatic hypotension during head up tilt test and all these were 
clinically asymptomatic. 
 
Table 8: Abnormalities in head up tilt table test in patients with CIDP 
 
 
Orthostatic hypotension 
 
n/t (%) 
                          
                                     Present 
 
5/23 (21.70) 
 
                                    Absent 
 
18/23(78.30) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Blood pressure and heart rate changes with head up tilt test, this fig. showing drop in 
blood pressure more than 40 mmHg. Red colour indicate blood pressure and blue colour indicate 
pulse rate. X-axis indicate time and Y- axis indicate pulse rate and blood pressure  
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Heart rate variability with deep breathing was detected in 15 of 23 patients. It was mild in 8 of 
23(34.8) patients and moderate in 7 of 23(30.4) patients. Valsalva ratio was abnormal in 15 of 
23(65.2%) patients and it was mild. 
Table 9: Heart rate variability with deep breathing and valsalva ratio in patients with 
CIDP 
 
 
Heart rate variation with deep breathing 
 
n/t (%) 
 
                     Normal 
 
8/23(34.8) 
 
                     Decreased ≥ 50% of minimum 
 
8/23(34.8) 
 
                     Decreased ≤ 50 % of minimum 
 
7/23(30.4) 
 
Valsalva ratio, n/t (%) 
 
                   
                   Normal 
 
 8/23(34.8) 
 
                  Decreased ≥ 50% of minimum                   
 
15/23(65.2) 
 
                 Decreased ≤ 50 % of minimum 
 
 0/23(0) 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 : Shows heart rate variation with deep 
breathing. Blue line indicates change in HR. 
Redline indicates changes in BP.  
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SSR was absent in 14 of 23 patients, It was absent in 12 of 23 in lower limbs and 2 0f 23 in both 
upper limbs and lower limbs. 
 
 
 
Table 10: SSR dysfunction in patients with CIDP  
 
SSR 
 
      n/t (%) 
 
Present in both upper limbs and lower 
limbs 
 
     9/23(39.2) 
 
Absent in lower limbs 
 
     12/23(52.2) 
 
Absent in both lower limbs and upper 
limbs 
 
     2/23(8.7) 
  
 
 
Table 11: Comparison of Heart rate variability parameters (assessed by 
power spectral analysis) and Valsalva ratio, RSA 
 
 
HRV variables 
Study group(n=23) 
Mean ± SD 
Control group(n=10) 
Mean ± SD 
 
P value 
 
HF nu at rest 
 
23.84  ± 21.12 
 
22.24 ± 26.26 
 
0.652 
 
LF nu at rest 
 
53.49 ± 4.16 
 
29.4 ± 26.57 
 
0.02 
 
HF nu at tilt 
 
21.7 ± 21.7 
 
17.5 ± 6.8 
 
 
0.214 
 
LF nu at tilt 
 
 
39.4 ±19.38 
 
49.8 ± 10.15 
 
0.116 
 
Valsalva Ratio 
1.39±0.23 1.88±0.35 <0.001 
 
RSA 
 
10.40 ±7.89 19.29±5.58 0.004 
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At Rest        
 
 
 
 
                                                                                            
 
 
 
 
 
 
 At Tilt 
Figure 5(Above):  HF and LF changes at rest and at 70degree tilt position in healthy individual.   
Figure 6(Below): HF and LF changes at rest and at 70degree tilt position in patient with CIDP 
with Sympathetic dysfunction. There was no increase in LF after tilting.  
X-axis indicate frequency and Y- axis indicate power. HF from 0.15Hz to 0.4 and LF from 0.004 
to o.15Hz 
 
 
Fig: 5 
Fig:6 
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DISCUSSION 
 
 
Majority of studies in literature are retrospective with paucity of prospective studies. There are 
no data from the India where the clinical profile and severity of illness might differ compared to 
the West. We studied the autonomic dysfunction in a prospective cohort of Indian patients with 
CIDP. The analysis included baseline demographic data, autonomic symptom profile, Total 
neuropathy score, quantitative autonomic function testing using tilt table test, heart rate 
variability analysis, sudomotor function testing using SSR.  
 
This study reveals relatively high prevalence of autonomic symptoms and abnormalities in 
quantitative autonomic function tests in patients with CIDP. The prevalence of clinical 
symptoms of autonomic dysfunction in our study was about 60%. Stamboulis et al (n=17) 
reported autonomic symptoms in 64% of CIDP patients.(7) Figueroa et al (n=47) reported 
autonomic symptoms in 20-30% of CIDP patients.(4) Chiang et al. reported symptoms of 
autonomic dysfunction in 20% of CIDP patients (n=18).(50)The variation in frequency of 
symptoms between studies could be due to less emphasis on autonomic symptoms and due to 
recall bias in retrospective studies. This emphasizes the need for a systematic questionnaire 
based approach for exact documentation of the profile of autonomic symptoms such as 
COMPASS 31.  
 
In this study we found that 19 of 23(82%) of CIDP patients had quantative autonomic 
dysfunction. In comparison, Stamboulis et al. (n=17) reported autonomic dysfunction in 76% of 
CIDP patients.(7) Figueroa et al (n=47) reported autonomic dysfunction in 47% of CIDP 
patients.(4) 
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The difference in prevalence of quantative autonomic dysfunction could be explained by study 
setting, methodology of autonomic function tests and temporal profile of disease. 
 
Among 19/23 of our patients had abnormal autonomic function tests, among them 15/19 had 
clinical symptoms suggestive of autonomic system involvement. Stamboulis et al. reported 
(n=17) autonomic function tests abnormalities in 13 patients, among them 10 had clinical 
symptoms indicative of autonomic involvement. It was comparable our study. 
 
In our study both parasympathetic and sympathetic systems were affected, cholinergic (70%) 
being more involved than adrenergic system (60%).Stamboulis et al. (n=17) reported both arms 
of autonomic systems were affected equally. Figueroa et al. (n=47) reported that cholinergic 
systems (40%) was involved predominantly with relative sparing of adrenergic system. 
 
Lyu et al. reported autonomic dysfunction in CIDP patients (n=12), which involved both arms of 
autonomic system equally.(6) 
 
 
In our study, the severity of autonomic dysfunction was assessed by using modified CAS 
scoring. In view of lack of facilities for  QSART, SSR was used to assess sudomotor functions. It 
was incorporated in to CAS scoring and a modified CAS score was used for analysis. SSR was 
abnormal in 60% of our study population; it was comparable to 50 % (n=12) by Lyu et al study. 
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The mean CAS score of our study population was 3.26±1.91. In comparison,  Figueroa et al 
reported mean CASS of 0.8±0.9 in patients with CIDP (n=47). Lyu et al. reported mean CASS of 
2.7±2.0 in patients with CIDP (n=12). (6)(4)Our study population had a high modified CASS 
compared to other published studies, which has not been validated yet. 
 
One important observation of our study was the high incidence of autonomic dysfunction. 
Majority of the patients were in clinical remission (complete/ partial) and were responders to the 
immunotherapy.  The involvement of sympathetic and parasympathetic arms of the autonomic 
nervous system can be explained by involvement of small myelinated and unmyelinated nerve 
fibres, vagal nerve dysfunction with conduction blocks, secondary axonal loss. Involvement of 
the intermediolateral cell column in the spinal cord as a result of “bystander effect” and axonal 
degeneration has also been proposed.  
 
Power spectrum analysis of heart rate variability was done by using Fourier analysis of regular 
beat-beat(R-R) intervals which were recorded for 5 min, converted in to a continuous function by 
linear interpolation and resample at 5Hz.  In power spectrum, LF indicates predominantly 
sympathetic and HF indicates parasympathetic activity. Though we could not overall find any 
significant differences with frequency domain analysis using FFT, a few important observations 
were made.  
 
In normal population, HF > LF during rest and LF > HF during standing/tilt. Tilting in normal 
individuals is usually associated with an increase in the low frequency components (sympathetic 
arm) with reciprocal decrease in high frequency component (parasympathetic dysfunction).  
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The CIDP patients in our cohort showed low LF power during the rest and the gain of LF during 
tilt was also suboptimal as compared to normal population indicating dysfunction of the 
sympathetic arm. 
 
Power spectral analysis of heart rate variability has been studied in patients with Guillain–Barre´ 
syndrome to assess cardiovascular neural regulation showing that the sympathovagal balance is 
clearly shifted to sympathetic predominance at the height of the disease.(68) To our knowledge 
the same has not been studied in CIDP patients. Our study is the first to clearly document 
sympathetic dysfunction  in CIDP cases using Power spectral analysis of Heart rate variability.  
 
In our study autonomic deficits did not relate to somatic deficits, duration of disease, severity of 
disease and temporal profile of disease. Quantitative autonomic function deficits were also 
independent of autonomic symptom profile indicates subclinical autonomic dysfunction as 
previously reported by Stamboulis et al. 
 
The autonomic dysfunction in our study was compared to autonomic dysfunction in amyloid 
neuropathy, small fiber neuropathy and other studies of CIDP with autonomic dysfunction as 
depicted in the table.  
Patients with amyloid amyloid neuropathy,diabetic LRPN,autoimmune autonomic ganglinopathy 
had high CAS scores. Small fiber neuropathy and CIDP patients had mild to moderate CAS 
scores.50 % of   patients with Small fiber neuropathy showed autonomic dysfunction. Whereas, 
studies with CIDP patients show variable involvement  (from 50 to 75%).  
Our study shows mild to moderate autonomic dysfunction documented with Modified CASS in 
at least 80% of cases. 
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Table 12: Comparison of CASS scores between our study with other studies (with CIDP and 
other neuropathies) reported in the literature. 
 
CASS total and severity distribution 
 
 
Neuropathic conditions 
Mean 0% Mild
(1-3) 
Moderate 
(4-6) 
Severe 
(7-10) 
 
CIDP (current study), mean (n -
23) 
3.27  17 35   48 0 
Cardiovascular autonomic 
function and SSR in CIDP by 
Lyu et al(n=12) (6) 
2.7 25 50   25 0 
Autonomic dysfunction in CIDP 
by Figueroa et al.(n=47) (4) 
0.8 
 
53 47    0 0 
 
Amyloid neuropathy, (n - 58) 
(70) 
6.7 0 10   42 48 
 
Sicca complex-neuropathy, (n -
34)(71) 
NA 15 38   35 12 
 
Autoimmune autonomic 
ganglionopathy, (n -27)(72) 
6.0 0 26  11 63 
 
Small-fiber neuropathy,(n -125) 
(73) 
2.7 48 24  27 1 
 
Diabetic LRPN,  (n - 14) (74) 
7.0 0 29  14 57 
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The major strength of the study is the prospective nature with detailed symptom profile assessed 
by COMPASS 31 score and quantitative autonomic function testing. Our study is the first to 
assess HRV in CIDP using power spectral analysis. It appears that CIDP patients tend to have 
higher incidence of autonomic dysfunction than previously reported in literature. The 
dysfunction also is not restricted and appears to involve multiple domains of the autonomic 
nervous system.  
 
Some of the limitations of the study include:  
1. Small sample size 
2. QSART was not done 
3. Modified CASS was done using SSR has not been validated yet. 
4. Patients are in remission at the time of testing 
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CONCLUSION 
 
 
1.There is a high Prevalence of autonomic dysfunction is in patients with CIDP (80%). 
 
 
2. The parasympathetic arm (70%)was more involved than sympathetic(60%). 
 
 
4. Spectral analysis of HRV showing abnormality in sympathetic arm. 
 
 
5.In our study 37 % had mild degree of autonomic dysfunction and 47% had moderate degree of 
autonomic dysfunction. 
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ANNEXURES I 
DATA COLLECTION PROFORMA 
             
Autonomic dysfunction in CIDP 
History                                                                 
 
 
 
 
 
 
 
 
 
 
Co-morbidities : 
Hypertension       Diabetes       
Smoking      Alcohol      
IHD       Obesity      
Organo phos exp                                           
Renal failure        Other toxins          
Native medication                                Chronic liver disease      
   
General Examination:     
Temp:   Pulse:            reg/irreg   
Blood pressure:  lying/   sitting/      standing/ 
 
Height:                       Weight:                         BMI :  
 
Name: 
 
Hospital Number: 
 
DOB:  Age: 
 
M/F     
Address: 
 
Telephone/E-mail: 
 
Seen by: 
 
Date:   Time: 
 
Serial number  
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Neurological examination: 
 
The Mini-Mental Status Examination (MMSE)  Points 
Orientation 
Name: season/date/day/month/year  
Name: hospital/floor/town/state/country 
  
5 (1 for each name) 
5 (1 for each name) 
Registration 
Identify three objects by name and ask patient to repeat 
  
3 (1 for each object) 
Attention and calculation 
Serial 7s; subtract from 100 (e.g., 93-86-79-72-65) 
  
5 (1 for each subtraction) 
Recall 
Recall the three objects presented earlier 
 3 (1 for each object) 
Language 
Name pencil and watch  
Repeat ‘‘No ifs, ands, or buts’’  
Follow a 3-step command (e.g., ‘‘Take this paper, fold it in half, and 
place it on the table’’) 
Write ‘‘close your eyes’’ and ask patient to obey written command 
Ask patient to write a sentence  
Ask patient to copy a design (e.g., intersecting pentagons) 
  
2 (1 for each object) 
1 
3 (1 for each command) 
  
1 
1 
1 
TOTAL  
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Cranial Nerves                                                                              0 = Normal , 1 =Abnormal  
Cranial nerves  
Olfactory   
Vision   
Fundus   
Eye movmnt  
Trigeminal   
Facial   
Vest Coclr   
 Palate   
Sternomastoid   
Tongue   
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                Motor  Examination  
 
      Bulk and Tone:                                 
                                                                                                           0 = Normal,  1 = Decreased , 3 Increased  
 
        Power                                                                                     
  
Power  R L 
Neck flx   
Neck ext   
Trunk    
Should Abd   
Should Add    
Elbow Flx   
Elbow Ext    
Wrist Flx    
Wrist Ext    
Hip Flx    
Hip Ext    
Knee Flx    
Knee Ext    
Dorsiflx    
Plantar   
                                                                                                                                                                         MRC Scale                                                                       
0 No contraction                                                                                                                                                       
                                                                                              1 Flicker or trace of contraction 
                                                                                      2 Active Movement with gravity eliminated                                                                           
3 Active Movement Against gravity 
                                                                                                         4 Active Movement Against gravity & resistance 
Reflexes  
 
  
Reflexes  R L 
Biceps    
Brachiorad    
Triceps    
Knee    
Ankle    
Sup abd   
Plantar   
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Sensory examination  
        
   
 Sensory  R L 
Up.Limb  Fine touch    
 Vibration    
 Temperature   
 Joint pos    
 Monofilamnt   
Lo.Limb Fine touch    
 Vibration    
 Temperature   
 Joint pos    
 Monofilamnt   
                                                              0 = Normal , 1 = Abnormal    ( quantify sensory loss in %  25/ 50 / 75/ 100) 
 
 
Cerebellar and Gait  
  
  
Cerebel  
Romber  
Gait  
Nk stif  
                                                                         0 = Normal, 1 = Abnormal                                                    
 Electrophysiology  
  
NCV   
EMG   
                                                                                                               0 = Normal, 1 = Abnormal 
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Investigations  
  
Hb   
TC  
DC   
Platelets  
Lipids   
AC  
PC   
Creat  
 
 
 
TOTAL NEUROPATHY SCORE 
 
Parameter 
Score 
0 1 2 3 4 
QST = quantitative sensory test; ULN = upper limit of normal; LLN = lower 
limit of normal. 
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Parameter 
Score 
0 1 2 3 4 
Sensory 
symptoms 
None Symptoms 
limited to 
fingers or 
toes 
Symptoms 
extend to 
ankle or 
wrist 
Symptoms 
extend to knee 
or elbow 
Symptoms 
above knees 
or elbows, 
or 
functionall
y disabling 
Motor 
symptoms 
None Slight 
difficulty 
Moderate 
difficulty 
Require 
help/assistanc
e 
Paralysis 
Autonomic 
symptoms, 
n 
0 1 2 3 4 or 5 
Pin 
sensibilit
y 
Normal Reduced in 
fingers/toe
s 
Reduced up 
to 
wrist/ankl
e 
Reduced up to 
elbow/knee 
Reduced to 
above 
elbow/knee 
Vibration 
sensibilit
y 
Normal Reduced in 
fingers/toe
s 
Reduced up 
to 
wrist/ankl
e 
Reduced up to 
elbow/knee 
Reduced to 
above 
elbow/knee 
Strength Normal Mild 
weakness 
Moderate 
weakness 
Severe 
weakness 
Paralysis 
Tendon 
reflexes 
Normal Ankle 
reflex 
reduced 
Ankle 
reflex 
absent 
Ankle reflex 
absent, others 
reduced 
All 
reflexes 
absent 
Vibration 
sensation 
(QST 
vibration) 
Normal to 
125% ULN 
126 to 150% 
ULN 
151 to 
200% ULN 
201 to 300% 
ULN 
>300% ULN 
Sural 
amplitude 
Normal/reduce
d to <5% LLN 
76 to 95% 
of LLN 
51 to 75% 
of LLN 
26 to 50% of 
LLN 
0 to 25% of 
LLN 
Peroneal 
amplitude 
Normal/reduce
d to <5% LLN 
76 to 95% 
of LLN 
51 to 75% 
of LLN 
26 to 50% of 
LLN 
0 to 25% of 
LLN 
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COMPASS 31 
1. In the past year, have you ever felt faint, dizzy, “goofy”, or had difficulty thinking soon after 
standing up from a sitting or lying position?  
1 Yes  
2 No   (if you marked No, please skip to question 5)  
  
2. When standing up, how frequently do you get these feelings or symptoms?  
1 Rarely  
2 Occasionally  
3 Frequently  
4 Almost Always  
  
3. How would you rate the severity of these feelings or symptoms?  
1 Mild  
2 Moderate  
3 Severe  
  
4. In the past year, have these feelings or symptoms that you have experienced:  
1 Gotten much worse  
2 Gotten somewhat worse  
3 Stayed about the same  
4 Gotten somewhat better  
5 Gotten much better  
6 Completely gone  
  
5. In the past year, have you ever noticed color changes in your skin, such as red, white, or purple?  
1 Yes  
2 No   (if you marked No, please skip to question 8)  
  
6. What parts of your body are affected by these color changes? (Check all that apply)  
1 Hands  
2 Feet  
  
7. Are these changes in your skin color:  
1 Getting much worse  
2 Getting somewhat worse  
3 Staying about the same  
4 Getting somewhat better  
5 Getting much better  
6 Completely gone  
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8. In the past 5 years, what changes, if any, have occurred in your general body sweating?  
1 I sweat much more than I used to  
2 I sweat somewhat more than I used to  
3 I haven’t noticed any changes in my sweating  
4 I sweat somewhat less than I used to  
5 I sweat much less than I used to  
  
9. Do your eyes feel excessively dry?  
1 Yes  
2 No  
  
10. Does you mouth feel excessively dry?  
1 Yes  
2 No  
  
11. For the symptom of dry eyes or dry mouth that you have had for the longest period of time, is this 
symptom:  
1 I have not had any of these symptoms  
2 Getting much worse  
3 Getting somewhat worse  
4 Staying about the same  
5 Getting somewhat better  
6 Getting much better  
7 Completely gone  
  
12. In the past year, have you noticed any changes in how quickly you get full when eating a meal?  
1 I get full a lot more quickly now than I used to  
2 I get full more quickly now than I used to  
3 I haven’t noticed any change  
4 I get full less quickly now than I used to  
5 I get full a lot less quickly now than I used to  
  
13. In the past year, have you felt excessively full or persistently full (bloated feeling) after a meal?  
1 Never  
2 Sometimes  
3 A lot of the time  
  
14. In the past year, have you vomited after a meal?  
1 Never  
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2 Sometimes  
3 A lot of the time  
  
15. In the past year, have you had a cramping or colicky abdominal pain?   
1 Never  
2 Sometimes  
3 A lot of the time  
  
16. In the past year, have you had any bouts of diarrhea?  
1 Yes  
2 No   (if you marked No, please skip to question 20)  
  
17. How frequently does this occur?  
1 Rarely  
2 Occasionally  
3 Frequently      ____________ times per month  
4 Constantly  
  
18. How severe are these bouts of diarrhea?  
1 Mild  
2 Moderate  
3 Severe  
  
19. Are your bouts of diarrhea getting:  
1 Much worse  
2 Somewhat worse   3  Staying the same  
  4  Somewhat better   5  Much 
better  
  6  Completely gone  
  
20. In the past year, have you been constipated?  
1 Yes  
2 No   (if you marked No, please skip to question 24)  
  
21. How frequently are you constipated?  
1 Rarely  
2 Occasionally  
3 Frequently      ____________ times per month  
4 Constantly  
  
22. How severe are these episodes of constipation?  
1 Mild  
62 
 
2 Moderate  
3 Severe  
  
  
  
23. Is your constipation getting:  
1 Much worse  
2 Somewhat worse   3  Staying the same  
  4  Somewhat better   5  Much 
better  
  6  Completely gone  
  
24. In the past year, have you ever lost control of your bladder function?  
1 Never  
2 Occasionally  
3 Frequently      ____________ times per month  
4 Constantly  
  
25. In the past year, have you had difficulty passing urine?  
1 Never  
2 Occasionally  
3 Frequently      ____________ times per month  
4 Constantly  
  
26. In the past year, have you had trouble completely emptying your bladder?  
1 Never  
2 Occasionally  
3 Frequently      ____________ times per month  
4 Constantly  
  
27. In the past year, without sunglasses or tinted glasses, has bright light bothered your eyes?  
1 Never (if you marked Never, please skip to question 29)  
2 Occasionally  
3 Frequently  
4 Constantly  
  
28. How severe is this sensitivity to bright light?  
1 Mild  
2 Moderate  
3 Severe  
  
29. In the past year, have you had trouble focusing your eyes?  
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1 Never (if you marked Never, please skip to question 31)  
2 Occasionally  
3 Frequently  
4 Constantly  
  
30. How severe is this focusing problem?  
1 Mild  
2 Moderate  
3 Severe  
31. Is the most troublesome symptom with your eyes (i.e. sensitivity to bright light or trouble focusing) 
getting:  
1 I have not had any of these symptoms  
2 Much worse  
3 Somewhat worse  
4 Staying about the same  
5 Somewhat better    
6 Much better  
7 Completely gone  
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Composite autonomic scoring system 
 
 
Index  
Score  Parameter 
 
Sudomotor index 
1 Single site abnormal on quantitative sudomotor axon reflex test or 
length dependent pattern (distal sweat volume <1/3 of proximal 
site or persistent sweat activity at foot(On TST, anhidrosis present 
but<25%) 
 
 
2 Single site <50% of lower limit of QSART (On TST, anhidrosis 
25-50%) 
 
 
3 Two or more sites < 50% of lower limit on QSART (On TST, 
anhidrosis >50%) 
 
Adrenergic index 
 
1 Early phase phase 2 decrease of <40 mmHg but >20 mmHg MAP 
or late phase 2 doses not return to baseline or decrease in pulse 
pressure to <50% of base line 
 
 
 
2 Early phase 2 decrease of <40 mmHg but >20 mmHg MAP  + late 
phase 2 doses not return to baseline or decrease in pulse pressure 
to <50% of base line 
 
 
 
3 Early phase 2 decrease of > 40 mmHg + absent laste phase 2 and 
phase 4 
 
 
4 Criteria for 3+ orthostatic hypotension(systolic BP decrease of >30 
mmHg: mean BP decrease of >20 mmHg) 
 
Cardiovagal index 
1 HRBD or VR mildly decreased( above 50% of minimum) 
 
 
 
2 HRBD or VR mildly decreased to 50% of minimum 
 
 
3 Both HRBD and VR mildly decreased to 50% of minimum 
 
 
 
 
 
65 
 
Grading of autonomic failure 
 
Composite autonomic scoring scale 
 
 
Degree of autonomic failure 
 
                             1-3 
  
         Mild 
 
                             4-6 
  
         Moderate 
 
                            7-10 
  
         Severe 
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EFNS/PNS 2010 criteria for diagnosis of CIDP: 
 
Inclusion criteria 
Patients diagnosed to have CIDP by EFNS/PNS 2010 criteria were included in the study. The 
criteria are mentioned below.  
 
[A] Clinical criteria 
 [1] Inclusion criteria 
(a) Typical CIDP  
Chronically progressive, stepwise, or recurrent symmetric proximal and distal   weakness 
and sensory dysfunction of all extremities, developing over at least 2 months; cranial 
nerves may be affected; and 
   Absent or reduced tendon reflexes in all extremities 
(b) Atypical CIDP (still considered CIDP but with different features) 
One of the following, but otherwise as in (a) (tendon reflexes may be normal in 
unaffected limbs): 
Predominantly distal (distal acquired demyelinating symmetric, DADS) or 
Asymmetric [multifocal acquired demyelinating sensory and motor neuropathy 
(MADSAM), Lewis–Sumner syndrome] or 
Focal (e.g., involvement of the brachial or lumbosacral plexus or of one or more 
peripheral nerves in one upper or lower limb) 
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Pure motor or Pure sensory (including chronic immune sensory polyradiculopathy 
affecting the central process of the primary sensory neuron) 
 [2] Exclusion criteria 
 
Borrelia burgdorferi infection (Lyme disease), diphtheria, drug or toxin exposure 
probably to have caused the neuropathy 
Hereditary demyelinating neuropathy 
Prominent sphincter disturbance 
Diagnosis of multifocal motor neuropathy 
IgM monoclonal gammopathy with high titre antibodies to myelin-associated 
glycoprotein 
Other causes for a demyelinating neuropathy including POEMS syndrome, osteosclerotic 
myeloma, diabetic and non-diabetic lumbosacral radiculoplexuneuropathy. PNS 
lymphoma and amyloidosis may occasionally have demyelinating features 
[B] Electro-diagnostic criteria: 
(1) Definite: at least one of the following 
(a) Motor distal latency prolongation ≥50% above ULN in two nerves (excluding median  at 
the wrist from carpal tunnel syndrome), or 
(b) Reduction of motor conduction velocity ≤30% below LLN in two nerves, or 
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(c) Prolongation of F-wave latency ≥30% above ULN in two nerves (≥50% if amplitude of 
distal negative peak CMAP <80% of LLN values), or 
(d) Absence of F-waves in two nerves if these nerves have distal negative peak CMAP 
amplitudes ≥20% of LLN + ≥1 other demyelinating parameters in ≥1 other nerve, or 
(e) Partial motor conduction block: ≥50% amplitude reduction of the proximal negative peak 
CMAP relative to distal, if distal negative peak CMAP ≥ 20% of LLN, in two nerves, or in 
one nerve + ≥1 other demyelinating parameters in ≥ 1 other nerve, or 
(f) Abnormal temporal dispersion (>30% duration increase between the proximal and distal 
negative peak CMAP) in ≥2 nerves, or 
(g) Distal CMAP duration (interval between onset of the first negative peak and return to 
baseline of the last negative peak) increase in ≥1 nerve 
(median≥ 6.6 ms, ulnar ≥ 6.7 ms, peroneal ≥ 7.6 ms, tibia ≥ l 8.8 ms) + ≥1 other 
demyelinating parameters in ≥1 other nerve 
(2) Probable 
≥30% amplitude reduction of the proximal negative peak CMAP relative to distal, excluding 
the posterior tibial nerve, if distal negative peak 
CMAP ≥ 20% of LLN, in two nerves, or in one nerve + ≥1 other demyelinating parametera 
in ≥1 other nerve 
(3) Possible 
As in (1) but in only one nerve 
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[C] Supportive criteria: 
1. Elevated CSF protein with leukocyte count <10/mm3  
2 .MRI showing gadolinium enhancement and/or hypertrophy of the cauda equina,             
lumbosacral or cervical nerve roots, or the brachial or lumbosacral plexuses  
3. Abnormal sensory electrophysiology in at least one nerve: 
a. Normal sural with abnormal median (excluding median neuropathy at the wrist 
from carpal tunnel syndrome) or radial sensory nerve action potential (SNAP) 
amplitudes; or 
b. Conduction velocity <80% of lower limit of normal (<70% if SNAP amplitude 
<80% of lower limit of normal); or 
c. Delayed somatosensory evoked potentials without central nervous system 
disease 
4. Objective clinical improvement following immunomodulatory treatment  
5. Nerve biopsy showing unequivocal evidence of demyelination and/or remyelination by 
electron microscopy or teased fiber analysis  
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Diagnostic categories 
Definite CIDP 
Clinical criteria 1 (a or b) and 2 with electrodiagnostic 
Criterion 1; or 
Probable CIDP + at least one supportive criterion; or 
Possible CIDP + at least two supportive criteria 
Probable CIDP 
Clinical criteria 1 (a or b) and 2 with electrodiagnostic 
Criterion 2; or 
Possible CIDP + at least one supportive criterion 
Possible CIDP 
Clinical criteria 1 (a or b) and 2 with electrodiagnostic criterion 3 
CIDP (definite, probable, and possible) associated with concomitant diseases 
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AUTONOMIC FUNCTION TESTS 
 
CARDIAC AND VASCULAR AUTONOMIC REGULATION TESTS: 
 
1. Cardiovascular Responses to Standing and 30:15 ratio: 
 
Studying blood pressure changes on standing is indicated in testing the integrity of the 
sympathetic adrenergic function. Studying heart rate changes to standing (30:15 ratio) is 
indicated in testing the integrity of parasympathetic cholinergic function. Measurements obtained 
after 20 min of supine rest. The blood pressure and heart rate are recorded at baseline and then 
serially for 1–3 min after postural standing. Orthostatic hypotension is present if there is a 
reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 
mmHg within 3 min of standing. The 30:15 ratio, which is the ratio of the longest R-R (slowest 
heart rate) occurring about 30 beats after standing, divided by the shortest R-R (fastest heart 
rate), which occurs about 15 beats after standing .(50)(51) Normally the 30:15 ratio is greater 
than 1.04 and abnormal if less than 1.0. More precise age-related norms are: 10–29 years, >1.17; 
30–49 years, >1.09; 50–65 years, >1.03.(52) 
 
2. Head-Up Tilt-Table Testing: 
Studying responses to tilt-table testing tests the integrity of the autonomic cardiovascular 
reflexes. The autonomic cardiovascular reflexes are similar but not identical to standing; 
After connecting and ensuring proper placement of blood pressure sensor, baseline blood 
pressure will be measured for 5-10 minutes. Then patient will be tilted up to 70 degree smoothly 
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within 5-10 seconds (ensuring patient safety) .Then blood pressure will be measured every 
minute. During this period patient will be observed for the presence of any discomfort, chest 
pain, shortness of breath, dizziness, lightheadedness, and syncope. In case of any sign of an 
emerging adverse event, test will be terminated based on clinical judgment. Duration of the tilt 
will be at least 10 minutes and continued for 30 minutes if no obvious abnormalities are detected 
.On completion of test patient will be tilted back to baseline position. The positive response is 
syncope or pre syncope associated with a significant drop of blood pressure (usually greater than 
20 mmHg systolic or 10 mmHg diastolic arterial pressure) or bradycardia. (53) 
 
3. Heart Rate Variation with Respiration (Sinus Arrhythmia): 
It tests the integrity of the parasympathetic cholinergic function. Inspiration increases heart rate, 
and expiration decreases it. The variation is primarily mediated by the vagus innervation of the 
heart. Sinus arrhythmia is influenced by several important factors. It decreases with age, CNS 
depressants, hyperventilation, cardiac failure and pulmonary diseases.The subject sits quietly and 
then breathes deeply at a rate of 6 breaths per minute. The ratio of the maximum – minimum 
heart rates to deep breathing is measured.  
Normal values by age for 6 per minute deep breathing expressed as average (or mean) maximal-
to-minimal variation in bpm are: 10–40 years, >18bpm; 41–50 years, >16 bpm; 
51–60 years, >12 bpm; 61–70 years, >8 bpm.(54)(55) 
 
 
4. Valsalva maneuver and Valsalva Ratio: 
It tests the integrity of both sympathetic and parasympathetic nervous systems. 
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The blood pressure changes during maneuver tests the sympathetic adrenergic cardiovascular 
function and heart rate changes during maneuver tests the parasympathetic cholinergic function. 
Valsalva maneuver will be performed in supine position; the test will be started after patient is 
comfortable and relaxed. 2-3 practice sessions of Valsalva maneuver for short time will be given 
until patient is comfortable with the procedure. Patient is instructed to take a deep breath and 
blow into the syringe which is connected to a manometer. Patient is asked to maintain a pressure 
of 40 mm Hg for 15 seconds. If the pressure is suboptimal, patient will be instructed to correct 
the pressure or repeat the Valsalva maneuver. Same procedure repeated after 3 minutes, total 3 
times and most appropriate maneuver will be selected for evaluation. The Valsalva maneuver has 
four phases as shown in the figure …. 
 
The following parameters will be measured from the Valsalva maneuver test – 
1. Valsalva ratio. 
2. Maximal drop of the mean blood pressure during phase 2. 
3. The peak of the mean blood pressure at the end of late phase 2 (recovery). 
4. Overshoot, phase 4. 
5. Maximal pulse pressure drop during phase 2 
 
The Valsalva ratio is the ratio of the maximal heart rate in phase II to the minimal heart rate in 
phase IV. This may be calculated easily as the ratio of the longest R-R interval during phase IV 
to the shortest of phase II. 
The Valsalva ratio of less than 1.2 as abnormal,1.2–1.45 as borderline, and greater than 1.45 as 
normal. Since the Valsalva ratio decreases with age, however, age specific norms are more 
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precise: 10–40 years,>1.5; 41–50 years, >1.45; 51–60 years, >1.45; 61–70 years, >1.35.(55)(54) 
The blood pressure drops of greater than 20 mmHg during early phase II in conjunction with 
either absent phase IV or absent late phase II are considered abnormal.  
 
Miscellaneous Tests for cardiac and vascular autonomic functions: 
 
1. Blood pressure response to sustained hand grip: 
Sustained muscle contraction causes blood pressure and heart rate to increase. 
The mechanism involves the exercise reflex, which withdraws parasympathetic activity and 
increases sympathetic activity.  
The test requires the patient to apply and maintain grip at 30% maximal activity for 3 min. The 
diastolic blood pressure should rise more than 15 mmHg above base line; 11–15 mmHg rise is 
considered borderline. There is less experience with this test, and it has not been widely 
studied.(56) 
 
 
 
 
2. Blood pressure response to mental stress: 
Mental stresses such as arithmetic, sudden noise and emotional pressure cause sympathetic 
outflow to increase and with it blood pressure and heart rate. It has been used as a measure of 
sympathetic efferent function that has the advantage of not requiring direct afferent stimulation, 
but the test lacks sensitivity.(57) 
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3. Cold pressor test: 
The patient submerges a hand in ice water, and subsequently there is a rise of  
blood pressure. The afferent limb of the reflex is somatic, and the efferent limb is sympathetic. 
The problems with the test are that it is difficult for many patients to maintain the hand in ice 
water for the requisite period of time, and the test lacks sensitivity, since many normal subjects 
do not have a significant rise of blood pressure. 
  
4. Plasma catecholamine levels and infusion tests: 
Normally upright posture induces vasopressor responses which are sympathetic and adrenergic, 
plasma norepinephrine levels nearly double. 
In a preganglionic sympathetic disorder such as multisystem atrophy, resting supine 
norepinephrine levels are normal but fail to rise when standing because of the lack of 
preganglionic drive. In postganglionic sympathetic disorders such as progressive autonomic 
failure, resting supine norepinephrine levels are low and fail to rise when standing. Since 
metabolic clearance of norepinephrine varies, sensitivity of the test may improve using indices of 
norepinephrine biosynthesis. Various infusions such as norepinephrine, tyramine, isoproterenol, 
phenylephrine, edrophonium, Vasopressin, and angiotensin have been studied to evaluate 
autonomic responses, including afferent baroreflex sensitivity.  
 
TESTS OF THERMOREGULATORY FUNCTION 
1. Sympathetic Skin Responses: 
The sympathetic skin response (SSR) test is a complex multi synaptic reflex with sudomotor 
76 
 
activity as final efferent arm. The SSR measures the evoked electro dermal activity. It is 
generated in sweat glands and surrounding dermis and epidermis in response to a stimulus. In a 
SSR, stimulation of somatic afferents results in activation of sympathetic, cholinergic, sudomotor 
post ganglionic axons which are the efferent components of somatosympathetic reflex response. 
The cerebral cortex, posterior hypothalamus, and ventro lateral brain stem reticular formation all 
affect the SSR. 
Electro dermal activity is brought out either directly or reflexly. A direct response is recorded by 
stimulating a peripheral nerve or sympathetic trunk, which evokes a time-locked potential. 
Because of the difficulty in achieving the high threshold for activation of the un myelinated C 
fibers and the unavoidable simultaneous activation of pain fibers, direct responses are not studied 
in a clinical setting. A reflex is brought out indirectly by a wide variety of stimuli which activate 
the sympathetic nervous system and bring out the potential. The main advantages of the SSR are 
that it is sensitive, reproducible, semi quantitative, simple, fast, and readily obtained on most 
electro physiologic equipment. 
The usual laboratory stimuli to elicit SSR are near noxious, electrical stimulation of sensory 
nerve preferably on a limb other than the one from which the response is recorded. Non noxious 
stimuli include mechanical, warm or cold thermal, startling auditory, emotional, deep inspiratory 
gasps, visual, mental stress etc. The SSR is usually recorded with standard surface electrodes 
with the active electrode on the palm of hand or plantar surface of foot, and a reference electrode 
on the dorsum of the same body part. 
The morphology of the potentials recorded was diphasic with an initial negative peak followed 
by a larger positive peak, but the response may be monophasic, triphasic, or have an initial peak. 
Potentials are symmetric in homologous body regions. The potentials in the hands have larger 
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amplitudes and shorter latencies than those in the feet. The SSR is controlled by conduction 
along unmyelinated fibers, and latency measurement is not useful. Initially regarded as an all-or-
none phenomenon, now as techniques are refined, amplitude criteria are defined. Amplitudes are 
difficult to define because of the variable morphology of the potential, but an increasing number 
of studies indicate usefulness of this parameter. According to Hoeldtke, latency in hands is 1.6 ± 
0.1 s, amplitude in hands is 1.3 ± 0.2 mV, latency in feet is 2.1 ± 0.1 s, and amplitude in feet is 
0.8 ± 0.1 mV. According to Knezevic, latency in hands is 1.5 ± 0.1 s, amplitude in hands is 0.5 ± 
0.1 mV, latency in feet is 2.1 ± 0.2 s, and amplitude in feet 0.1 ± 0.04 mV. According to Drory, 
mean latency in hands is 1.5 s, mean amplitude in hands is 0.450 mV, mean latency in feet is 1.9 
s, and mean amplitude in feet is 0.15 mV. (58)(59)(60) Patients with significant sensory 
neuropathy and reduced or absent somatic afferent input may not have electrically induced SSR, 
but may have EDA in response to some of the other stimuli noted above. This distinction could 
help differentiate sensory neuropathy with autonomic neuropathy from sensory neuropathy 
without autonomic involvement. 
 
 
2. Quantitative sudomotor axon reflex test: 
The QSART quantitatively assesses postganglionic sympathetic sudomotor axon and sweat gland 
function. QSART requires a multi compartmental sweat capsule and a sudometer.The different 
compartments of the sweat capsule allow for both stimulation and pickup of the sweating 
response. Stimulation requires a constant current generator which applies a current over one of 
the compartments to iontophorese acetylcholine onto the skin. The acetylcholine is 
iontophoresed at 2 mA for 5 min. Axon reflexes are generated when acetylcholine activates 
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nicotinic receptors in the sudomotor fiber terminal, sending impulses antidromically to branch 
points and then orthodromically back to remote neurosecretory synapses. In this way, the 
sudomotor axon is stimulated chemically, not electrically, by acetylcholine iontophoresis. Since 
this also stimulates sweat glands directly, the site of evaluation of the subsequent sweating 
responses is remote from the site of stimulation in a different compartment. Measurement 
requires a sudometer, which measures humidity. Low-humidity nitrogen gas is piped through the 
sudorometer to measure baseline or input humidity. The gas passes into the sweat compartment 
of the sweat capsule through an intake port and then exits the compartment through a different 
port. The gas passing over the skin is humidified by the sweat. It passes back to the sudorometer 
where the humidity is remeasured. The differences between the output and input humidities are 
recorded and quantified as a function of time. Recording continues for 5 min after cessation of 
the iontophoresis. The multi compartmental sweat cells are placed over four locations: the foot 
laterally in the distribution of the sural nerve, the distal leg proximal to the medial malleolus in 
the distribution of the saphenous nerve, the proximal leg just distal to the fibular head in the 
distribution of the peroneal nerve, and in the forearm medially in the distribution of the medial 
antebranchial nerve. QSART directly measures the activity of the postganglionic neurosecretory 
unit, allows delineation of proximal-to-distal topography, and provides a dynamic record of 
sudomotor function over time. 
 
3. Thermoregulatory Sweat Test: 
The TST is a sensitive test that provides quantative information on the distribution and pattern of 
sudomotor impairment.TST is dependent upon normal function of the pre ganglionic and post 
ganglionic components of sudomotor pathways.A powder contains alizarin red, which is orange 
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when dry but turns a deep purple color when sweating occurs, is applied to the forehead and the 
anterior surface of body. The patient is the put in a heated cabinet or heat cradle to provide a 
thermal stimulus that will increase the body temperature to 38° C or 1°C above the base line.  An 
ambient temperature of 45° to 50° C,  relative humidity of 30-40% and skin temperature of 39-
40° C to cause generalized sweating with in 50 min in most normal subjects.The TST in 
combination with QSART helps to differentiate autonomic dysfunction is preganglionic or post 
ganglionic origin. 
 
MISCELLANEOUS TESTS OF AUTONOMIC REGULATION: 
1. Tests of Exocrine and Pupillary Regulation: 
Sympathetic activity causes pupil dilation and contraction of Mueller’s muscle in the upper lid. 
Parasympathetic activity causes pupil constriction, accommodation, lacrimation, and salivation. 
Pupillary function is often assessed by pharmacological testing. Pilocarpine and methacholine 
are parasympathomimetic agents which act directly on cholinergic parasympathetic constrictor 
muscles to cause pupillary constriction. In dilute amounts (pilocarpine 0.125% or methacholine 
2.5% solution), they cause minimal constriction, but when there is parasympathetic denervation, 
there is denervation hypersensitivity, and the pupil constricts. Cocaine (4–5% solution) blocks 
reuptake of norepinephrine in sympathetic nerve terminals innervating papillary dilator muscles, 
and it causes pupillary dilation. In sympathetic denervation, norepinephrine is not present, and 
dilation does not occur when cocaine is applied.It helps in differentiating physiological 
anisocoria and sympathetic denervation. Hydroxyamphetamine is a sympathomimetic agent that 
releases norepinephrine; if the pupil fails to dilate when it is applied, the site of sympathetic 
denervation is postganglionic. Epinephrine acts directly on sympathetic adrenergic dilatory 
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muscles to cause pupillary dilation. In dilute amounts (0.1% solution), it normally causes 
minimal dilation, but when there is sympathetic denervation, there is denervation 
hypersensitivity, and the pupil dilates and it further confirms post ganglionic lesion. Lacrimation 
can be measured with the Schirmer’s test. In the Schirmer’s test, the wick end of a filter paper 
test strip is placed between the lower lid and the sclera. The length of wetting at 5 min is then 
measured,10 mm or more being normal. The sensitivity in detecting dry eyes is about 90%, and 
the specificity is about 85%. Salivation may be tested by having patients chew a series of five 
gauze pads for 1 min each for a total of 5 min after the sublingual gutter is wiped dry. Pretest 
weight is subtracted from posttest weight to calculate saliva production, normally greater than 
7.5 mL/5 min. 
 
 
2. Tests of Gastrointestinal Autonomic Regulation: 
Videofluoroscopy and pharyngoesophageal motility studies help identify causes of dysphagia. GI 
motility, including gastric emptying times and colonic transit times, allows for identification of 
neurogenic disorders, but does not distinguish extrinsic autonomic disorders from intrinsic 
enteric nervous system disorders. Sympathetic denervation may be identified by various 
neurochemical studies including the norepinephrine and epinephrine responses to edrophonium, 
which rise promptly after intravenous administration when there is normal post ganglionic 
innervation. Parasympathetic denervation may be identified by the plasma pancreatic 
polypeptide response to sham feeding or hypoglycemia. Anorectal manometry helps identify 
causes of incontinence. 
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3. Tests of Genitourinary Autonomic Regulation: 
Urodynamic studies in incontinent patients helps in identifying autonomic dysfunction. 
Tests of male erectile function, such as nocturnal tumescence studies and penile rigidity studies, 
assess erectile function, which is largely controlled by vascular and autonomic function If 
abnormal, injection of vasoactive agents such as papaverine into the corpus cavernosum helps 
differentiate vascular from nonvascular dysfunction, poor response to injection means the cause 
is vascular. 
 
 
 
 
 
 
 
 
 
Sno Hospno Name Sex Age Onset Duration Course Presentatio
1 384024F Sanjay garo 1 49 42 7 2 0
2 521935c Kasipandia 1 71 62 9 2 0
3 792294f Kamal hald 1 34 32 2 1 0
4 266411f Shajahan 1 53 51 2 2 1
5 802528f Annamma A 2 53 52 1 2 0
6 7772641f Dipak moda 1 29 28 1 1 0
7 822957c Ghan shyam 1 53 45 8 2 0
8 534698d Sunil Pradh 1 43 39 4 2 1
9 769768f Balasubran 1 63 59 4 2 1
10 113950f Amit tiwari 1 29 27 2 1 0
70 817657f Indra 2 61 60 1 1 0
12 811648f Annapurna 2 56 53 3 1 0
13 793581f Suresh pras 1 39 37 2 1 0
14 509670d Abraham 1 43 39 4 1 0
15 708664f Santhosh k 1 42 34 8 1 0
16 826855d Mishri Pras 1 54 50 4 2 0
17 415991c Ramjee mis 1 66 57 9 1 #NULL!
18 358713f Ashok Pal 1 46 44 2 1 #NULL!
19 837687f Sahad 1 33 32 1 1 #NULL!
20 901989F Aditya kum 1 15 15 4 3 #NULL!
21 752331F Prathap Ch 1 49 49 4 3 #NULL!
22 775677F Hari Prasad 1 44 43 1 1 #NULL!
23 042661D Nilratan 1 60 40 20 2 #NULL!
24 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
25 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
26 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
27 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
28 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
29 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
31 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
32 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
33 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
34 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
restotherapAss EFNSelectroCSFcells CSfprot Biopsy TNS COMPASS3OH
0 0 1 6 61 0 27 9 1
0 1 3 2 26 1 25 22 1
0 2 1 4 74 5 24 6 0
1 2 1 2 258 4 14 0 0
0 2 3 4 43 1 21 7 0
0 2 1 7 74 5 15 7 0
0 0 1 7 173 6 15 3 0
0 0 1 5 379 5 25 9 0
2 2 1 8 109 1 22 5 0
0 2 3 2 42 1 14 0 0
2 2 1 4 89 1 17 8 1
2 0 1 3 54 6 23 15 1
0 0 1 2 128 4 23 6 0
0 2 3 8 59 1 27 3 0
2 0 1 16 371 1 26 6 0
0 2 1 4 90 1 19 4 0
0 2 3 1 76 0 9 12 1
0 0 3 0 0 1 25 10 0
0 2 1 1 206 3 22 9 1
0 2 1 22 44 5 19 3 0
0 2 1 2 151 1 18 6 0
2 2 1 3 62 5 20 4 0
0 2 1 1 125 1 16 #NULL! 0
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2 2 0 0 1 1 3 1 1
0 0 0 1 1 0 4 2 2
0 0 0 0 0 0 3 1 0
2 1 0 0 0 0 5 2 2
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1 0 0 0 1 0 4 2 1
0 1 0 0 1 1 4 2 2
2 2 0 0 0 1 3 1 1
0 0 0 0 0 0 0 0 0
2 0 0 0 0 1 6 2 1
0 1 0 0 1 1 5 2 1
2 0 0 0 3 1 3 1 2
0 0 4 1 0 0 0 0 0
2 1 0 0 1 0 4 2 1
2 0 2 0 0 1 5 2 1
0 0 4 1 3 1 2 1 2
2 0 4 1 1 1 4 2 1
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Adrenergic SSR Blad Tilt Brea Breath Valasalv Valsa Mdr
1 1 #NULL! 0 8.16 1 1 1.18 13
1 1 #NULL! 0 1.83 2 1 1.07 0
1 1 #NULL! 0 3 2 1 1.34 0
2 1 #NULL! 0 10 0 0 1.36 21
3 0 #NULL! 1 4 2 1 1.21 11
0 1 #NULL! 0 11.6 1 0 1.59 10
3 0 #NULL! 1 15.8 0 1 1.32 17
2 0 #NULL! 0 4 2 1 1.22 17
2 0 #NULL! 0 4.6 1 0 1.6 26
0 0 #NULL! 0 22.5 0 0 1.64 14
4 1 #NULL! 1 5.83 1 1 1.27 49
3 1 #NULL! 1 35.16 0 1 1.36 16
0 1 #NULL! 0 2.83 2 1 1.15 0
0 0 #NULL! 0 11.4 0 0 1.52 0
2 1 #NULL! 0 9.5 1 0 1.57 34
3 1 #NULL! 0 13.33 0 1 1.3 42
0 1 #NULL! 0 2.6 2 1 1.28 0
0 2 #NULL! 0 18 0 1 1.1 0
2 0 #NULL! 0 10 1 1 1.26 12
0 0 #NULL! 0 18.2 0 0 2 14
4 1 #NULL! 1 9.3 1 0 1.55 32
1 2 #NULL! 0 3.5 2 0 1.47 0
0 0 #NULL! 0 14.1 0 0 1.8 0
#NULL! #NULL! #NULL! #NULL! 32.8 #NULL! #NULL! 2.4 #NULL!
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#NULL! #NULL! #NULL! #NULL! 17.83 #NULL! #NULL! 1.52 #NULL!
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Maxbp recovery over Systolic Diastolic Mean Systolic30 Diastolic30Mean30
0 0 1 130 75 97 115 75 90
0 1 1 172 76 110 143 61 89
0 1 1 133 81 104 141 96 115
1 0 1 150 86 109 128 78 95
0 0 0 140 82 103 120 81 97
0 1 1 118 74 93 105 70 85
0 0 0 151 99 118 124 78 97
0 1 0 113 74 95 126 81 101
1 0 1 104 76 86 75 61 67
0 1 1 128 76 94 121 76 93
2 0 0 168 76 108 112 62 77
0 0 1 160 83 112 146 95 116
0 1 1 151 104 120 120 101 99
0 1 1 130 80 100 103 100 97
1 0 0 170 100 130 160 109 125
2 0 0 140 81 106 141 78 103
0 1 1 139 82 108 111 78 94
0 1 1 107 56 77 95 59 74
0 1 1 139 70 98 124 71 91
0 1 1 117 81 101 116 83 98
1 0 0 154 84 114 99 54 67
0 0 1 148 67 93 142 72 94
0 1 1 138 67 89 116 65 82
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138 76 96 150 87 108 144 75 98
92 65 74 98 69 78 111 71 84
111 78 89 121 79 93 124 84 97
108 74 82 100 69 79 97 70 79
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113 49 70 123 54 77 121 46 71
136 61 84 130 73 92 145 74 97
137 82 100 145 89 107 150 91 110
122 77 92 121 81 94 116 78 89
174 118 136 179 120 139 158 103 121
138 74 95 138 76 96 128 75 92
115 80 91 121 81 94 116 73 87
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114 82 96 118 85 104 112 82 98
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120 67 85 128 67 90 120 66 85
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128 80 96 92 100 105 97 93 94
164 71 102 74 73 74 72 73 73
138 90 166 79 85 81 81 84 82
164 82 110 65 89 40 88 88 81
129 79 92 69 85 79 96 78 67
107 67 80 90 93 98 98 102 107
138 83 107 91 89 96 92 95 86
124 81 98 94 103 103 98 98 99
90 70 78 85 87 88 92 88 91
131 85 100 86 94 96 90 98 100
157 70 100 82 90 89 90 90 88
146 82 108 104 82 108 107 113 81
139 89 105 108 120 105 106 109 112
118 81 93 98 65 102 101 105 100
170 108 129 84 88 88 90 72 80
131 74 93 76 77 71 70 75 65
127 80 95 76 79 81 79 77 79
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2 1 1 1 1 1 0.000735 4E‐05 0.000483
2 1 1 2 0 1 0.00922 0.003705 0.004878
2 1 1 2 1 1 1.09E‐05 1.09E‐05 5.22E‐08
2 1 2 0 2 1 0.0422 0.01819 0.02061
2 1 1 2 3 0 0.000102 3.35E‐05 6.08E‐05
2 1 1 1 0 1 0.00434 0.001078 0.002759
2 1 1 1 3 0 0.00146 3.81E‐05 0.000429
2 1 1 2 2 0 0.0148 1.15E‐07 5.17E‐07
2 2 2 1 2 0 0.0015 0.000273 0.000709
2 2 2 0 0 0 0.000333 2.04E‐05 0.000185
2 1 1 1 4 1 0.00621 0.002152 0.003595
2 1 1 1 3 1 0.00471 0.001472 0.002011
2 1 1 2 0 1 0.00095 0.000221 0.000554
2 1 1 0 0 0 0.024 0.003862 0.01601
2 1 1 1 2 1 0.000712 8.06E‐05 0.000408
2 1 1 1 4 1 0.00176 0.000501 0.000806
2 1 1 2 0 0 4.84E‐05 3.74E‐06 1.77E‐05
2 1 1 1 0 3 0.000264 9.52E‐06 0.000103
2 1 1 1 2 0 0.000912 0.000108 0.000632
2 1 1 0 0 0 0.0094 0.002457 0.005287
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2 2 2 2 1 0 0.0284 0.0048 0.0137
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#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! 0.00651 0.002467 0.003075
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! 0.00129 0.000227 0.000592
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! 0.015 0.01366 0.01036
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! 0.138 0.002376 0.009432
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
TotalT HFT LFT HFnu LFNUrest patcontrol HFnutilt lfNUTILT
0.000338 2.16E‐05 0.000117 0.0544 0.657 1 0.064 0.346
1.09E‐05 1.08E‐05 0 0.402 0.529 1 0.995 #NULL!
0.000598 0.000226 1.24E‐05 0.996 #NULL! 1 0.378 0.0207
0.0452 0.02799 0.009323 0.431 0.488 1 0.619 0.206
0.000359 0.000101 0.000215 0.328 0.596 1 0.282 0.599
0.00891 4.81E‐08 2.09E‐07 0.248 0.636 1 #NULL! #NULL!
0.0011 0.000242 0.000638 0.0261 0.294 1 0.22 0.58
0.000269 2.65E‐05 0.000103 #NULL! #NULL! 1 0.0986 0.384
0.00429 0.000949 0.002398 0.182 0.473 1 0.221 0.559
0.000313 2.37E‐05 0.000118 0.0613 0.556 1 0.0758 0.377
0.000482 0.000127 0.000185 0.347 0.579 1 0.264 0.384
0.00173 0.000391 0.01083 0.313 0.427 1 0.226 #NULL!
0.00466 0.000855 0.002744 0.232 0.583 1 0.183 0.589
0.00503 0.001186 0.002806 0.161 0.667 1 0.236 0.558
0.00119 9.81E‐05 0.000676 0.113 0.573 1 0.0824 0.568
0.000759 7.34E‐05 0.000429 0.285 0.458 1 0.0967 0.565
0.00323 0.00079 0.002 0.0772 0.365 1 0.245 0.619
0.000319 8.93E‐06 0.000103 0.036 0.392 1 0.028 0.322
0.000843 4.81E‐05 0.000525 0.118 0.693 1 0.0571 0.623
0.00255 0.000215 0.001638 0.261 0.562 1 0.0842 0.642
0.00242 0.000557 0.01399 0.167 0.649 1 0.23 #NULL!
0.0255 0.005589 0.01418 0.169 0.482 1 0.219 0.556
0.000589 4.9E‐05 0.000327 0.181 0.628 1 0.0832 0.555
0.0254 0.005587 0.01417 0.1631 0.482 2 0.22 0.558
0.00323 0.00079 0.002 #NULL! #NULL! 2 0.245 0.619
0.000313 2.37E‐05 0.000118 0.0061 0.0556 2 0.0757 0.377
0.000141 1.81E‐05 6.31E‐05 0.1451 0.712 2 0.128 0.448
0.0017 0.000154 0.01167 0.1405 0.485 2 0.0908 #NULL!
0.00139 0.000363 0.000932 0.1062 #NULL! 2 0.261 0.671
0.0114 0.002731 0.00703 0.379 0.472 2 0.24 0.617
0.0068 0.001029 0.004038 0.1758 0.459 2 0.151 0.594
0.00996 0.00212 0.00635 0.9107 0.691 2 0.213 0.638
0.00513 0.000633 0.002337 0.0172 0.0683 2 0.123 0.456
#NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
